15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
"15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A stable prostaglandin endoperoxide analog which serves as a thromboxane mimetic. Its actions include mimicking the hydro-osmotic effect of VASOPRESSIN and activation of TYPE C PHOSPHOLIPASES. (From J Pharmacol Exp Ther 1983;224(1): 108-117; Biochem J 1984;222(1):103-110)
| Descriptor ID |
D019796
|
| MeSH Number(s) |
D01.248.497.158.685.750.744.650.500.500 D01.339.431.374.744.650.500.500 D01.650.550.750.700.650.500.500 D02.389.338.638.650.500.500 D10.251.355.255.550.025.650.500.500 D23.469.050.175.725.025.650.500.500 D23.469.700.630.500
|
| Concept/Terms |
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid- 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
- 9,11-Dideoxy-11 alpha,9-alpha-epoxymethano-PGF2 alpha
- 9,11-epoxymethano-PGH2
- 9,11 epoxymethano PGH2
- 11 alpha,9 alpha-Epoxymethano PGH2
- 11 alpha,9 alpha Epoxymethano PGH2
- (15S)hydroxy-9alpha,11alpha-(epoxymethano)prosta-5,13-dienoic acid
- (15S)-Hydroxy-11 alpha, 9 alpha-(epoxymethano)prosta-5Z, 13E-dienoic Acid
- 9,11-Dideoxy-11 alpha,9 alpha-epoxymethanoprostaglandin F2 alpha
U-44619- U-44619
- U 44619
- U46619
- U44619
- U-46619
- U 46619
|
Below are MeSH descriptors whose meaning is more general than "15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid".
- Chemicals and Drugs [D]
- Inorganic Chemicals [D01]
- Electrolytes [D01.248]
- Ions [D01.248.497]
- Anions [D01.248.497.158]
- Oxides [D01.248.497.158.685]
- Peroxides [D01.248.497.158.685.750]
- Prostaglandin Endoperoxides [D01.248.497.158.685.750.744]
- Prostaglandins H [D01.248.497.158.685.750.744.650]
- Prostaglandin H2 [D01.248.497.158.685.750.744.650.500]
- 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid [D01.248.497.158.685.750.744.650.500.500]
- Free Radicals [D01.339]
- Reactive Oxygen Species [D01.339.431]
- Peroxides [D01.339.431.374]
- Prostaglandin Endoperoxides [D01.339.431.374.744]
- Prostaglandins H [D01.339.431.374.744.650]
- Prostaglandin H2 [D01.339.431.374.744.650.500]
- 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid [D01.339.431.374.744.650.500.500]
- Oxygen Compounds [D01.650]
- Oxides [D01.650.550]
- Peroxides [D01.650.550.750]
- Prostaglandin Endoperoxides [D01.650.550.750.700]
- Prostaglandins H [D01.650.550.750.700.650]
- Prostaglandin H2 [D01.650.550.750.700.650.500]
- 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid [D01.650.550.750.700.650.500.500]
- Organic Chemicals [D02]
- Free Radicals [D02.389]
- Peroxides [D02.389.338]
- Prostaglandin Endoperoxides [D02.389.338.638]
- Prostaglandins H [D02.389.338.638.650]
- Prostaglandin H2 [D02.389.338.638.650.500]
- 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid [D02.389.338.638.650.500.500]
- Lipids [D10]
- Fatty Acids [D10.251]
- Fatty Acids, Unsaturated [D10.251.355]
- Eicosanoids [D10.251.355.255]
- Prostaglandins [D10.251.355.255.550]
- Prostaglandin Endoperoxides [D10.251.355.255.550.025]
- Prostaglandins H [D10.251.355.255.550.025.650]
- Prostaglandin H2 [D10.251.355.255.550.025.650.500]
- 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid [D10.251.355.255.550.025.650.500.500]
- Biological Factors [D23]
- Inflammation Mediators [D23.469]
- Autacoids [D23.469.050]
- Eicosanoids [D23.469.050.175]
- Prostaglandins [D23.469.050.175.725]
- Prostaglandin Endoperoxides [D23.469.050.175.725.025]
- Prostaglandins H [D23.469.050.175.725.025.650]
- Prostaglandin H2 [D23.469.050.175.725.025.650.500]
- 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid [D23.469.050.175.725.025.650.500.500]
- Prostaglandins, Synthetic [D23.469.700]
- Prostaglandin Endoperoxides, Synthetic [D23.469.700.630]
- 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid [D23.469.700.630.500]
Below are MeSH descriptors whose meaning is more specific than "15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid".
This graph shows the total number of publications written about "15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid" by people in this website by year, and whether "15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 1 | 2 |
| 2001 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid" by people in Profiles.
-
Newaz M, Yousefipour Z, Oyekan A. Natriuretic and renoprotective effect of chronic oral neutral endopeptidase inhibition in acute renal failure. Ren Fail. 2010 Jan; 32(3):384-90.
-
Yousefipour Z, Hercule H, Truong L, Oyekan A, Newaz M. Ciglitazone, a peroxisome proliferator-activated receptor gamma inducer, ameliorates renal preglomerular production and activity of angiotensin II and thromboxane A2 in glycerol-induced acute renal failure. J Pharmacol Exp Ther. 2007 Aug; 322(2):461-8.
-
Newaz M, Yousefipour Z, Oyekan A. Role of PPAR-gamma on the pathogenesis and vascular changes in glycerol-induced acute renal failure. Pharmacol Res. 2006 Sep; 54(3):234-40.
-
Yakubu MA, Leffler CW. Regulation of cerebral microvascular endothelial cell cyclooxygenase-2 message and activity by blood derived vasoactive agents. Brain Res Bull. 2005 Dec 30; 68(3):150-6.
-
Oyekan AO. Contributions of nitric oxide and prostanoids and their signaling pathways to the renal medullary vasodilator effect of U46619 (9-11-dideoxy-11 alpha,9a-epoxymethano-prostaglandin F(2a)) in the rat. J Pharmacol Exp Ther. 2003 Feb; 304(2):507-12.
-
Opere CA, Awe SO, Harris LC, LeDay AM, Ohia SE. Potentiation of sympathetic neurotransmission in bovine isolated irides by isoprostanes. Free Radic Res. 2001 Sep; 35(3):257-64.
-
Awe SO, Opere CA, Harris LC, Uketui AJ, Ohia SE. Effect of isoprostanes on sympathetic neurotransmission in the human isolated iris-ciliary body. Neurochem Res. 2000 Apr; 25(4):491-6.
-
Yakubu MA, Leffler CW. Enhanced pial arteriolar sensitivity to bioactive agents following exposure to endothelin-1. Life Sci. 2000; 66(4):307-16.